By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
IndebtaIndebta
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
IndebtaIndebta
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
Indebta > News > Pfizer: Ridiculous Selloff To A 2-Year Low (NYSE:PFE)
News

Pfizer: Ridiculous Selloff To A 2-Year Low (NYSE:PFE)

News Room
Last updated: 2023/05/18 at 3:29 PM
By News Room
Share
6 Min Read
SHARE

Pfizer Inc. (NYSE:PFE) investors continued their mad scramble out of the leading big pharma company after its recent earnings release. In my early March update, I discussed why PFE dip buyers could be attracted to return as it closes in against critical long-term moving averages or MA.

However, my upgrade turned out to be premature, as the momentary recovery was stunted by early April, as sellers rotated out of stocks with significant exposure to the COVID vaccine franchises.

As such, stocks of COVID vaccine leaders such as Pfizer, Moderna (MRNA), and BioNTech (BNTX) were not spared from the mayhem, as they continued their downward spiral.

PFE and BNTX dropped toward a two-year low, while MRNA looks primed to re-test the critical support of its consolidation range. In addition, they significantly underperformed the Healthcare Select Sector ETF (XLV) since the start of 2023, as investors worry about the revenue exposure from their COVID franchises.

Even though Pfizer performed well in Q1, surpassing the consensus estimates, market operators aren’t having it. As the market is forward-looking, the move to de-risk the contribution of their COVID revenues further has caused a “catching a falling knife” predicament for dip buyers.

Management prudently cautioned that the company “anticipates a decrease in Covid-19 vaccine utilization this year as the pandemic evolves.” However, it also expects a strong transition to the private commercial model, suggesting “higher sales for Comirnaty and Paxlovid in 2024.”

However, I assessed that Wall Street remains tentative over the company’s projections, given the execution risks of the model transition. In addition, Jefferies indicated that management’s outlook for its COVID vaccine revenue could be overstated. Coupled with the loss of exclusivity or LOE on “certain drugs” starting from 2026, investors are right to worry about whether Pfizer can recover from these headwinds.

Revised Wall Street estimates indicate that they concur with management’s guidance on full-year revenue and adjusted EPS. Analysts expect Pfizer to post revenue of $68.1B (down 32% YoY) and an adjusted EPS of $3.37 (down 49% YoY) for FY23.

As such, I don’t think investors had fully priced in the growth risks for 2023, as it fell dramatically from its December 2022 highs. Therefore, the continued slide in PFE hitting two-year lows is incredibly frustrating.

PFE quant factor ratings

PFE quant factor ratings (Seeking Alpha)

However, a glance at PFE’s factor ratings could provide useful clues into the market’s intentions. Seeking Alpha Quant rated PFE’s growth ratings with an “F” grade, the worst possible.

Hence, the weak grade relative to its sector peers could have driven the rotation away from PFE, given the relative underperformance.

PFE quant factor ratings

PFE quant factor ratings (Seeking Alpha)

Despite that, PFE’s “A-” valuation grade suggests that long-term dip buyers could still find it attractive to return if they have conviction over the performance of management to drive shareholder value.

Management attempted to shore up shareholder confidence at its recent earnings release. It highlighted a shift in capital allocation priorities moving forward, with a “focus towards dividends and share buybacks.”

However, with a forward dividend yield of 4.5% (Vs. 10Y average of 3.6%), it likely isn’t enough to placate income investors to pile in, with the 2Y Treasury still printing 4.17%.

Moreover, the company issued long-term debt worth $31B to finance its relatively expensive Seagen (SGEN) acquisition, increasing its execution risks on a deal some could still view as a “show-me story.”

With total debt falling to about $36.2B in Q1, management is under pressure to deliver the value proposition with its Seagen deal. However, market operators didn’t seem to like it, as PFE continued to decline over the past few weeks.

PFE price chart (weekly)

PFE price chart (weekly) (TradingView)

As seen above, the selloff has been brutal on investors, as PFE collapsed since forming its December 2022 highs.

It has also broken below its 50-month MA (blue line), which previously attracted long-term buyers to return. However, I have yet to glean constructive price action suggesting buyers are willing to lean in and bolster PFE at the current levels.

Despite that, I have confidence in Pfizer’s wide-moat business model and its ability to navigate its recent acquisitions as it attempts to create $45B in new long-term revenue streams by 2030, overcoming the loss of $17B from the LOEs.

I assessed that the risk/reward still points to the upside from here, with the next possible support zone close to the $33 level. Hence, investors are encouraged to keep some spare ammo to dollar-cost average if necessary.

Rating: Strong Buy (Reiterated).

Important note: Investors are reminded to do their own due diligence and not rely on the information provided as financial advice. The rating is also not intended to time a specific entry/exit at the point of writing, unless otherwise specified.

We Want To Hear From You

Have additional commentary to improve our thesis? Spotted a critical gap in our thesis? Saw something important that we didn’t? Agree or disagree? Comment below and let us know why, and help everyone in the community to learn better!

Read the full article here

News Room May 18, 2023 May 18, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
Private equity hit by deal slump as trade fears rise

Watch full video on YouTube

How Kohl’s Kicked Off Another Meme Stock Frenzy

Watch full video on YouTube

Starbucks Corporation (SBUX) Q3 2025 Earnings Call Transcript

Starbucks Corporation (NASDAQ:SBUX) Q3 2025 Earnings Conference Call July 29, 2025 4:15…

UBS orders bankers to scale back sale of complex currency products

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

Investors should not be taking risks right now amid geopolitical uncertainty, analyst says

Watch full video on YouTube

- Advertisement -
Ad imageAd image

You Might Also Like

News

Starbucks Corporation (SBUX) Q3 2025 Earnings Call Transcript

By News Room
News

UBS orders bankers to scale back sale of complex currency products

By News Room
News

JPMorgan Chase Stock’s Newest 6% Bond Appears Better Than CDs Or Treasuries (NYSE:JPM)

By News Room
News

Fidelity Overseas Fund Q2 2025 Commentary (Mutual Fund:FOSFX)

By News Room
News

Empire State Realty Trust, Inc. (ESRT) Q2 2025 Earnings Call Transcript

By News Room
News

Crown Castle Inc. 2025 Q2 – Results – Earnings Call Presentation (NYSE:CCI)

By News Room
News

Microsoft poaches top Google DeepMind staff in AI talent war

By News Room
News

White Brook Capital Partners Q2 2025 Commentary

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?